Tomas Lindahl Nobel Laureate Laboratory, Precision Medicine Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China.
Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
Int J Mol Sci. 2021 May 26;22(11):5672. doi: 10.3390/ijms22115672.
COVID-19 has rapidly become a pandemic worldwide, causing extensive and long-term health issues. There is an urgent need to identify therapies that limit SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Unbalanced lung inflammation is a common feature in severe COVID-19 patients; therefore, reducing lung inflammation can undoubtedly benefit the clinical manifestations. Histamine H1 receptor (H1 receptor) antagonists are widely prescribed medications to treat allergic diseases, while recently it has emerged that they show significant promise as anti-SARS-CoV-2 agents. Here, we briefly summarize the novel use of H1 receptor antagonists in combating SARS-CoV-2 infection. We also describe the potential antiviral mechanisms of H1 receptor antagonists on SARS-CoV-2. Finally, the opportunities and challenges of the use of H1 receptor antagonists in managing COVID-19 are discussed.
COVID-19 已迅速在全球范围内成为大流行疾病，导致广泛且长期的健康问题。目前迫切需要确定能够限制 SARS-CoV-2 感染并改善 COVID-19 患者预后的疗法。失衡的肺部炎症是重症 COVID-19 患者的常见特征；因此，减轻肺部炎症无疑将有益于临床症状。组胺 H1 受体（H1 受体）拮抗剂是广泛用于治疗过敏疾病的处方药物，而最近发现它们作为抗 SARS-CoV-2 药物具有显著的应用前景。在这里，我们简要总结了 H1 受体拮抗剂在对抗 SARS-CoV-2 感染中的新用途。我们还描述了 H1 受体拮抗剂对 SARS-CoV-2 的潜在抗病毒机制。最后，讨论了在管理 COVID-19 中使用 H1 受体拮抗剂的机会和挑战。
